S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Ra Medical Systems Stock Forecast, Price & News

-0.16 (-7.17%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
215,677 shs
Average Volume
1.96 million shs
Market Capitalization
$14.55 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RMED News and Ratings via Email

Sign-up to receive the latest news and ratings for Ra Medical Systems and its competitors with MarketBeat's FREE daily newsletter.

Ra Medical Systems logo

About Ra Medical Systems

Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of dermatologic and cardiovascular diseases. The firm's product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. It operates through the following segments: Dermatology and Vascular. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Carlsbad, CA.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Year Founded

Sales & Book Value

Annual Sales
$4.41 million
Book Value
$7.24 per share


Net Income
$-36.04 million
Net Margins
Pretax Margin




Free Float
Market Cap
$14.55 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

2.03 out of 5 stars

Medical Sector

586th out of 1,392 stocks

Surgical & Medical Instruments Industry

60th out of 127 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Ra Medical Systems (NYSE:RMED) Frequently Asked Questions

Is Ra Medical Systems a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ra Medical Systems in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ra Medical Systems stock.
View analyst ratings for Ra Medical Systems
or view top-rated stocks.

How has Ra Medical Systems' stock been impacted by Coronavirus (COVID-19)?

Ra Medical Systems' stock was trading at $31.4075 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RMED stock has decreased by 93.4% and is now trading at $2.07.
View which stocks have been most impacted by COVID-19

How were Ra Medical Systems' earnings last quarter?

Ra Medical Systems, Inc. (NYSE:RMED) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.79) by $0.36. Ra Medical Systems had a negative trailing twelve-month return on equity of 148.62% and a negative net margin of 721.86%.
View Ra Medical Systems' earnings history

When did Ra Medical Systems' stock split? How did Ra Medical Systems' stock split work?

Ra Medical Systems shares reverse split on the morning of Tuesday, November 17th 2020. The 1-25 reverse split was announced on Monday, November 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 16th 2020. An investor that had 100 shares of Ra Medical Systems stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for RMED?

2 equities research analysts have issued 12-month target prices for Ra Medical Systems' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Ra Medical Systems' share price to reach $12.00 in the next year. This suggests a possible upside of 479.7% from the stock's current price.
View analysts' price targets for Ra Medical Systems
or view top-rated stocks among Wall Street analysts.

Who are Ra Medical Systems' key executives?

Ra Medical Systems' management team includes the following people:
  • Jonathan Will McGuire, Chief Executive Officer & Director
  • Andrew C. Jackson, Chief Financial Officer
  • Alvin Memmolo, VP-Clinical, Quality & Regulatory Affairs
  • Christopher Folk, Vice President-Engineering
  • Maria Villanueva Sessions, Vice President & Compliance Officer

What other stocks do shareholders of Ra Medical Systems own?

When did Ra Medical Systems IPO?

(RMED) raised $50 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor served as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

What is Ra Medical Systems' stock symbol?

Ra Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

Who are Ra Medical Systems' major shareholders?

Ra Medical Systems' stock is owned by many different institutional and retail investors. Top institutional investors include GSA Capital Partners LLP (0.75%), Geode Capital Management LLC (0.59%), Bank of New York Mellon Corp (0.38%), Citadel Advisors LLC (0.30%), Jane Street Group LLC (0.20%) and Avantax Planning Partners Inc. (0.14%). Company insiders that own Ra Medical Systems stock include Andrew C Jackson, Dean Irwin, Jonathan Will Mcguire, Martin Burstein, Martin J Colombatto, Richard Mejia Jr and William R Enquist.
View institutional ownership trends for Ra Medical Systems

Which major investors are selling Ra Medical Systems stock?

RMED stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have sold Ra Medical Systems company stock in the last year include Andrew C Jackson, and Jonathan Will Mcguire.
View insider buying and selling activity for Ra Medical Systems
or view top insider-selling stocks.

Which major investors are buying Ra Medical Systems stock?

RMED stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Bank of New York Mellon Corp, Citadel Advisors LLC, Jane Street Group LLC, and Avantax Planning Partners Inc.. Company insiders that have bought Ra Medical Systems stock in the last two years include Jonathan Will Mcguire, Martin J Colombatto, Richard Mejia Jr, and William R Enquist.
View insider buying and selling activity for Ra Medical Systems
or or view top insider-buying stocks.

How do I buy shares of Ra Medical Systems?

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ra Medical Systems' stock price today?

One share of RMED stock can currently be purchased for approximately $2.07.

How much money does Ra Medical Systems make?

Ra Medical Systems has a market capitalization of $14.55 million and generates $4.41 million in revenue each year. The company earns $-36.04 million in net income (profit) each year or ($10.62) on an earnings per share basis.

How many employees does Ra Medical Systems have?

Ra Medical Systems employs 85 workers across the globe.

What is Ra Medical Systems' official website?

The official website for Ra Medical Systems is www.ramed.com.

Where are Ra Medical Systems' headquarters?

Ra Medical Systems is headquartered at 2070 Las Palmas Drive, Carlsbad CA, 92011.

How can I contact Ra Medical Systems?

Ra Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at (760) 804-1648 or via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.